Huanggang Wellman Biotechnology Co., Ltd. is located in the Yangtze River New Area Science and Technology Industrial Park, Huangzhou District, Huanggang City, Hubei Province. It is a chemical pharmaceutical manufacturing enterprise (C2710) specializing in research and development (R&D) and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and high-end generic drugs. The company is simultaneously advancing large-scale mass production and international regulatory registration. Its registered capital amounts to RMB 30 million, fully paid in.  

The company primarily engages in the R&D, production, and export of antiviral nucleoside APIs and key intermediates—such as the Azvudine intermediate (CAS No. 1927858-76-3) and the Emtricitabine side-chain derivative—serving innovative pharmaceutical companies, international generic drug manufacturers, and CDMO partners. It has established stable delivery capabilities at the intersection of fine chemical engineering and high-end pharmaceutical manufacturing.  

Its core competencies encompass the development and engineering application of green process packages integrating “enzyme catalysis—continuous-flow microreaction—multi-step crystallization purification.” The company possesses design and operational experience for GMP-compliant workshops capable of producing APIs at capacities ranging from metric-ton to 20 metric tons per year. It maintains a dedicated R&D team of 56 personnel and holds 11 authorized invention patents. Its technological achievements have reduced solvent consumption by 62% and decreased wastewater COD by 58%, earning it the Second Prize of Hubei Provincial Science and Technology Progress Award in 2024.  

In terms of qualifications, the company holds a “Pharmaceutical Production License” (Category Code: cghz); has passed dynamic inspections under China’s Good Manufacturing Practice (GMP) Guidelines (2010 Revision) and ICH Q7 (Hubei Provincial Drug Administration Permit No. [2024] 189); and is certified to ISO 9001:2015 and ISO 14001:2015. It is recognized as a National High-Tech Enterprise (GR202142002387) and a Hubei Provincial “Specialized, Refined, Distinctive, and Innovative” Small- and Medium-Sized Enterprise (Hubei Provincial Department of Industry and Information Technology Letter No. [2022] 178).  

Notable accomplishments include serving as the core domestic supplier of Azvudine API for a leading Chinese innovative antiviral pharmaceutical company; completing the main file submission for the European Union Certificate of a Suitability of the Monograph of the European Pharmacopoeia (CEP) (EDQM Application No.: CEP 2023-XXX); activating its Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) (DMF No.: 32891); achieving RMB 120 million in intermediate exports to Sun Pharma (India) in 2024; and participating in a key national R&D program task focused on engineering implementation of continuous-flow microreactors.  

The company’s current business operations span 21 provinces and municipalities within China, as well as 12 countries including India, Brazil, and Egypt. It has initiated pre-registration under the EU REACH Regulation (Pre-registration No.: 01-2121519920-52-XXXX). It supports collaboration modes including technology licensing, regulatory documentation support, customized intermediate supply, and joint regulatory filings. Publicly available information does not indicate the establishment of overseas legal entities or independent end-product brand development by the company.